1. Home
  2. PASG vs HBIO Comparison

PASG vs HBIO Comparison

Compare PASG & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PASG

Passage Bio Inc.

HOLD

Current Price

$5.20

Market Cap

26.0M

Sector

Health Care

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$5.52

Market Cap

24.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PASG
HBIO
Founded
2017
1901
Country
United States
United States
Employees
27
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
26.0M
24.9M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
PASG
HBIO
Price
$5.20
$5.52
Analyst Decision
Buy
Buy
Analyst Count
7
2
Target Price
$14.00
$18.00
AVG Volume (30 Days)
64.6K
28.4K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
N/A
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.28
52 Week High
$20.00
$7.50

Technical Indicators

Market Signals
Indicator
PASG
HBIO
Relative Strength Index (RSI) 42.65 47.35
Support Level $3.94 $4.42
Resistance Level $5.74 $5.79
Average True Range (ATR) 0.38 0.46
MACD 0.18 -0.18
Stochastic Oscillator 69.53 24.52

Price Performance

Historical Comparison
PASG
HBIO

About PASG Passage Bio Inc.

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: